Medical Therapy. Adverse Effects or Lack of Adverse Effects

The Role of Nitric oxide in the sweep gas for patients receiving Extracorporeal Membrane Oxygenation or Cardiopulmonary Bypass

Roberto Chiletti, Sophie H. Fincher, Stephen B. Horton, Giles J. Peek, Paul Checchia, Warwick ButtRoyal Children’s Hospital and University of Melbourne. University of Florida. Texas Children’s Hospital and the Baylor College of Medicine. Australia and United States Canadian Journal of CardiologyCan J Cardiol 2024; DOI: 10.1016/j.cjca.2024.12.027 AbstractNitric oxide (NO) was proclaimed the 1992 “molecule of the […]

The Role of Nitric oxide in the sweep gas for patients receiving Extracorporeal Membrane Oxygenation or Cardiopulmonary Bypass Read More »

Treprostinil Use in the NICU

Diana LeeUniversity of Pennsylvania School of Nursing.United States Advances in Neonatal CareAdv Neonat Care 2024; 24: 554-560DOI: 10.1097/ANC.0000000000001218 AbstractBackground: Treprostinil is a prostacyclin analogue that is frequently used in the pediatric and adult population to treat pulmonary hypertension; however, it is not often a drug of choice for patients in the neonatal intensive care unit (NICU).Purpose: To evaluate

Treprostinil Use in the NICU Read More »

Oral sildenafil versus bosentan for treatment of persistent pulmonary hypertension of the newborn: a randomized controlled trial

Aditya Kallimath, Sujata Deshpande, Pari Singh, Reema Garegrat, Satyan Lakshminrusimha, Rajesh Maheshwari, Pradeep SuryawanshiBharati Vidyapeeth (Deemed to be University) Medical College. Imperial College. University of California Davis Children’s Hospital. Westmead Hospital.India, United Kingdom, United States and Australia BioMedical Central PediatricsBMC Pediatr 2024; 24: DOI: 10.1186/s12887-024-05107-0 AbstractBackground: Access to inhaled nitric oxide (iNO) is limited in low resource

Oral sildenafil versus bosentan for treatment of persistent pulmonary hypertension of the newborn: a randomized controlled trial Read More »

Oxygen saturation targets in neonatal care: A narrative review

Tri C. Nguyen, Rajeshwari Madappa, Heather M. Siefkes, Michelle J. Lim, Kanya Mysore Siddegowda, Satyan LakshminrusimhaKaiser Permanente North California. SIGMA Hospital. University of California Davis Children’s Hospital.United States Early Human DevelopmentEarly Hum Dev 2024; 199:DOI: 10.1016/j.earlhumdev.2024.106134 AbstractOptimal oxygenation requires the delivery of oxygen to meet tissue metabolic demands while minimizing hypoxic pulmonary vasoconstriction and oxygen toxicity.

Oxygen saturation targets in neonatal care: A narrative review Read More »

Current Pharmaceutical Strategies in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN): A Comprehensive Review of Therapeutic Agents

Divyanshi Kaplish, Jayant D. Vagha, Sachin Rathod, Aditya JainJawaharlal Nehru Medical College and Datta Meghe Institute of Higher Education and Research.India CureusCureus 2024; 16: DOI: 10.7759/cureus.70307 AbstractPersistent Pulmonary Hypertension of the Newborn (PPHN) is a life-threatening condition characterized by the failure of normal circulatory transition after birth, leading to sustained pulmonary hypertension and severe hypoxemia. Despite

Current Pharmaceutical Strategies in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN): A Comprehensive Review of Therapeutic Agents Read More »

Vasopressin induced hyponatremia in infants <3 months of age in the neonatal intensive care unit

Kavita Patel, Sharon Thomson, Meera Vijayan, Marjorie Makoni, Peter N. Johnson, Katy Stephens, Stephen B. Neely, Jamie L. MillerUniversity Health, San Antonio. Oklahoma Children’s Hospital at Oklahoma University Health, University of Oklahoma College of Medicine and University of Oklahoma College of Pharmacy. Lucile Packard Children’s Hospital. United States Frontiers in PediatricsFront Pediatr 2024; 12DOI: 10.3389/fped.2024.1465785 AbstractObjectives: Vasopressin

Vasopressin induced hyponatremia in infants <3 months of age in the neonatal intensive care unit Read More »

Massive pulmonary thromboembolism in an adolescent with SARS-CoV-2 infection

Verónica Chauriye Kuncar, Cecilia Castillo Acevedo, Carlos Acuña Aguirre, Piaignacia Díaz EspejoHospital Luis Calvo Mackenna.Chile Archivos Argentinos De PediatriaArch Argent Pediatr 2024; DOI: 10.5546/aap.2024-10474.eng AbstractThromboembolic events incidence is low in pediatrics; high suspicion and explicit management algorithms are essential. We present a 12-year-old female patient with two weeks of dyspnea, orthopnea, and ankle edema. Tests showed

Massive pulmonary thromboembolism in an adolescent with SARS-CoV-2 infection Read More »

Nintedanib preserves lung growth and prevents pulmonary hypertension in a hyperoxia-induced lung injury model

Kathy L. Ding, Caroline Smith, Gregory Seedorf, Steven H. AbmanUniversity of Colorado School of Medicine.United States Pediatric ResearchPediatr Res 2024; DOI: 10.1038/s41390-024-03562-0 AbstractBackground: Bronchopulmonary dysplasia (BPD), the chronic lung disease associated with prematurity, is characterized by poor alveolar and vascular growth, interstitial fibrosis, and pulmonary hypertension (PH). Although multifactorial in origin, the pathophysiology of BPD is partly

Nintedanib preserves lung growth and prevents pulmonary hypertension in a hyperoxia-induced lung injury model Read More »

A Belgian consensus on sotatercept for the treatment of pulmonary arterial hypertension

Jean-Luc Vachiéry, Catharina Brlge, Bjorn Cools, An Damen, Fabian Demeure, Michel De Pauw, Céline Dewachter, Daniel De Wolf, Laurence Gabriel, Laurent Godinas, Julien Guiot, Steven Haine, Mathias Leys, Marc Meysman, Anne-Catherine-Pouleur, Davis Ruttens, Els Vansteenkiste, Wendy Vansteenkiste, Thierry Weber, Gil Wirtz, Marion DelcroixHôpital Universitaire de Bruxelles Erasme. University Hospitals of Leuven and University of Leuven.

A Belgian consensus on sotatercept for the treatment of pulmonary arterial hypertension Read More »

Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension

Marius M. Hoeper, David B. Badesch, H. Ardeschir Ghofrani, J. Simon R. Gibbs, Mardi Gomberg-Maitland, Valerie V. McLaughlin, Ioana R. Preston, Rogerio Souza, Aaron B. Waxman, Ekkehard Grünig, Grzegorz Kopeć, Gisela Meyer, Karen M. Olsson, Stephan Rosenkranz, Yayun Xu, Barry Miller, Marcie Fowler, John Butler, Jeorg Koglin, Janethe de Oliveira Pena, and Marc Humbert, for

Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension Read More »

Scroll to Top